Stocktoria
Pulmonx Corp LUNG
Pulmonx Corp (LUNG) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $90.5M at a -59.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.27 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.631 |
| Retained earnings / assets | -4.034 |
| EBIT / assets | -0.415 |
| Equity / liabilities | 0.72 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LUNG | Pulmonx Corp | 3/9 | -11.04 | — | +8% |
| KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | 5/9 | -0.94 | — | +59% |
| DCTH | DELCATH SYSTEMS, INC. | 6/9 | 1.26 | 165.4 | +129.1% |
| IRMD | IRADIMED CORP | 5/9 | 14.84 | 53.4 | +14.4% |
| NPCE | NeuroPace Inc | 5/9 | -13.13 | — | +25.1% |
| BBNX | Beta Bionics, Inc. | 4/9 | 6.94 | — | +53.9% |
| TELA | TELA Bio, Inc. | 3/9 | -13.97 | — | +15.8% |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
FAQ
Is LUNG financially healthy?
Pulmonx Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does LUNG pay a dividend?
No, Pulmonx Corp does not currently pay a dividend.
How profitable is LUNG?
In FY2025, Pulmonx Corp had a net margin of -59.7% and a return on equity of -99.8%.
What is the analyst price target for LUNG?
The average Wall-Street price target for Pulmonx Corp is $3.40, about 48.5% above the recent price, from 5 analysts.
Is LUNG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Pulmonx Corp: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.